索拉非尼联合蒽环类化疗药对乳腺癌MCF-7细胞增殖周期的影响

目的探讨索拉非尼联合蒽环类化疗药表阿霉素对乳腺癌MCF-7细胞增殖周期的作用。方法细胞做四甲基偶氮唑盐实验,绘制细胞增殖曲线。实验分为4组：对照组、索拉非尼单药组、表阿霉素单药组、联合组（索拉非尼＋表阿霉素）。用聚酰亚胺染色后,经流式细胞仪检测各组细胞增殖周期的变化。结果细胞增殖曲线可见细胞传代后开始增殖,4~5 d达到峰值,后随着时间的延长,细胞增殖受抑越来越明显。流式细胞仪检测细胞周期结果显示,索拉非尼单药组使MCF-7细胞阻滞于G0/G1期[（62.837±0.511）%]与对照组[（49.250±0.826）%]比较,差异有统计学意义（P〈0.05）;表阿霉素单药组使细胞阻滞于S期[（24.976±0.409）%],与对照组[（23.473±1.009）%]比较,差异有统计学意义（P〈0.05）;联合组G0/G1期细胞比率[（64.373±0.429）%]高于对照组及表阿霉素单药组[（50.980±0.403）%],差异均有统计学意义（均P〈0.05）。结论索拉非尼和表阿霉素的联合应用可以使乳腺癌MCF-7细胞明显阻滞于G0/G1,可以为乳腺癌的联合化疗提供一定的理论依据。

Affect of the Coadministration of Sorafenib and anthracycline chemotherapy drug on the cell cycle of breast cancer MCF-7 cell

Objective To investigate the affect of Sorafenib combined with anthracycline chemotherapy Epirubicin on the proliferation of breast cancer MCF-7 cell cycle. Methods Cells growth curve were drawn after the MTr experiment. Four different groups were set up＂ control group, Sorafenib group, EPI group and Sorafenib＋EPI （combination） group. The change of cell cycles were detected by PI single staining and flow cytometry. Results Cell growth curve showed, passaged ceils began to proliferate, and reached the peak after 4-5 days, with the prolongation of time, cell proliferation was inhibited more and more obvious. The cell cycle by flow cytometry showed that, the Sorafenib group [（62.837± 0.511）%] induced Go/Gl phase mitosis arrest, compared with control group [（49.250±0.826）%], the difference was statistically significant （P 〈 0.05）; the EPI group （24.976±0.409）%] induced accumulation of S phase mitosis arrest, compared with control group [（23.473±1.009）%], the difference was statistically significant （P 〈 0.05）; and the combination group [（64.373 ±0.429）%] showed greater increase of Go/G1 phase, compared with control group and EPI group [（50.980±0.403）%], the differences were statistically significant （P 〈 0.05）. Conclusion The combined application of Sorafenib and Epirubicin can make the breast cancer MCF-7 cells arrested in Go/G1, provide certain theoretical basis for the combination chemotherapy for breast cancer.